Evan Dunn, MD
Urology · Lewiston, MENPI 1790928570
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,977 of the $9,256 with a category attached, or 64.6%. 39 manufacturers reported payments, led by Ambu A/s at 30.1% of the total. Reporting peaked in 2024 at $3,979 and has fallen 57.5% since, to $1,692 in 2025. Among urology clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 165 payments — averaging $56.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ambu A/s$3K
- Axonics, Inc.$2K
- Boston Scientific$643
- Procept Biorobotics Corporation$587
- Sumitomo Pharma America, Inc.$301
- AbbVie$277
- plus $3K from 33 others
What the payments were for
- Consulting fees$2,78230%
- Speaking & faculty fees$2953%
- Travel & lodging$1882%
- Food & beverage$5,97765%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ambu A/s | 1 | $2,782 |
| Axonics, Inc. | 33 | $1,876 |
| Boston Scientific | 8 | $643 |
| Procept Biorobotics Corporation | 6 | $587 |
| Sumitomo Pharma America, Inc. | 10 | $301 |
| AbbVie(2 entities) | 14 | $277 |
| Olympus America Inc. | 3 | $251 |
| Johnson & Johnson(2 entities) | 6 | $201 |
| Endo Pharmaceuticals Inc. | 8 | $164 |
| Endo USA, Inc. | 7 | $160 |
| Integra Lifesciences Corporation | 1 | $159 |
| Calyxo, Inc. | 1 | $153 |
| Ferring Pharmaceuticals Inc. | 6 | $136 |
| Pfizer | 6 | $131 |
| Tolmar, Inc. | 5 | $129 |
| 180 Medical, Inc. | 5 | $128 |
| Rochester Medical Corporation | 4 | $125 |
| Ambu Inc. | 5 | $119 |
| Astellas Pharma US Inc | 4 | $98 |
| Urogen Pharma, Inc. | 2 | $95 |
| Laborie Medical Technologies Corp. | 1 | $80 |
| Bayer | 4 | $71 |
| Merck | 3 | $70 |
| Myriad Genetic Laboratories, Inc. | 3 | $61 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $55 |
| Progenics Pharmaceuticals, Inc. | 2 | $51 |
| Caldera Medical, Inc | 1 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Covidien LP | 1 | $38 |
| Coloplast | 1 | $34 |
| Novartis | 1 | $27 |
| Genentech USA, Inc. | 1 | $26 |
| Teleflex LLC | 1 | $24 |
| Intercept Pharmaceuticals, Inc. | 1 | $23 |
| Urovant Sciences Inc | 1 | $21 |
| Madrigal Pharmaceuticals | 1 | $20 |
| Halozyme Inc | 1 | $19 |
| Mimedx Group, Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$856
- Bulkamid$531
- INTEGRA$477
- AquaBeam Robotic System$386
- REZUM$311
- Axonics r-SNM System$228
- INTEGRA DERMAL REGENERATION TEMPLATE$159
- PRIMATRIX$159
- CVAC Aspiration System$153
- AMS$125
- Olympus Ureteroscopes$122
- GEMTESA$117
- iTIND System$110
- LithoVue$105
How this compares
$9,256 in reported general payments places this provider in the 90th percentile of 59 urology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 106 | $61,623 |
| MyrbetriqMirabegron | 84 | $55,107 |
| Testosterone | 16 | $4,421 |
| Solifenacin Succinate | 48 | $3,753 |
| Tamsulosin Hcl | 304 | $3,107 |
| Oxybutynin Chloride ErOxybutynin Chloride | 126 | $3,093 |
| Tolterodine Tartrate ErTolterodine Tartrate | 26 | $1,984 |
| Trimethoprim | 22 | $1,919 |
| Desmopressin Acetate | 19 | $1,749 |
| Oxybutynin Chloride | 108 | $1,589 |
| NitrofurantoinNitrofurantoin Macrocrystal | 20 | $1,285 |
| Finasteride | 105 | $1,147 |
| Testosterone Cypionate | 14 | $1,012 |
| Estradiol | 23 | $942 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 167 | $582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $301 | $61,623106 claims |
| Astellas Pharma US IncMyrbetriq | $98 | $55,10784 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 59 urology providers in Maine.
Other urology in Lewiston
- Christopher HenryLewiston$6K
- Michael ParkerLewiston$4K
- Christopher FooteLewiston$4K
- Jordan KurtaLewiston$2K
- Griffith BatstoneFarmington$123K
- David SobelPortland$58K
- Marc HodroffPortland$17K
- Robert FisherRockport$9K
- Jesse SammonSouth Portland$6K
- Sanchita BoseSouth Portland$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.